Sage Therapeutics Insider Cashes Out Equity After Supernus Acquisition Close
Rhea-AI Filing Summary
Director Michael F. Cola filed a Form 4 after Sage Therapeutics (SAGE) completed its merger with Supernus Pharmaceuticals on 07/31/2025. The agreement paid shareholders $8.50 cash plus one contingent value right (CVR) of up to $3.50 per share.
Cola’s only reported transaction is the disposition of 21,500 stock options with a $6.77 exercise price. At the effective time, all in-the-money options vested automatically and were cancelled in exchange for: (i) cash equal to the spread between the $8.50 merger price and the $6.77 strike (≈ $1.73 per option) and (ii) one CVR for each underlying share. Options with strike prices at or above $8.50 were cancelled for no consideration, leaving the reporting person with zero derivative securities in the issuer.
The filing confirms the merger’s close, cash payout mechanics, and termination of Section 16 insider status.
Positive
- Merger consummation: Filing confirms Sage’s cash-and-CVR sale to Supernus closed on 07/31/2025.
- Cash payout clarity: Shareholders and option-holders receive $8.50 per share plus potential $3.50 CVR, eliminating deal uncertainty.
Negative
- Out-of-the-money options canceled: Any option with a strike ≥ $8.50 was terminated with no consideration, erasing potential upside for those holders.
Insights
TL;DR: Merger closed; director options cashed out at $8.50 + CVR—no ongoing SAGE exposure.
The Form 4 is primarily procedural, documenting conversion of 21,500 in-the-money options into cash and CVRs once the Supernus takeover became effective. While insider “selling” can appear bearish, the action is automatic under the merger agreement and does not reflect discretionary sentiment. Importantly, it confirms payment terms—$8.50 cash plus up to $3.50 CVR—are now binding. Investors holding SAGE should no longer expect equity upside beyond CVR milestones. Impact is neutral to slightly positive because it evidences deal completion and cash realization.
TL;DR: Filing formalizes option cancellation terms, ensuring compliance post-merger.
The disclosure satisfies Section 16 requirements by documenting how board-level equity was treated at close. Automatic vesting of unexercised options removes potential post-close conflicts and signals that legacy incentive plans are extinguished. Options with strikes ≥ $8.50 were canceled without payment, illustrating equitable application of the merger terms. Overall governance impact is neutral; the event merely codifies contractual obligations already disclosed in the proxy and tender offer materials.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option (Right to Buy) | 21,500 | $0.00 | -- |
Footnotes (1)
- This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 13, 2025, among Sage Therapeutics, Inc. (the "Issuer"), Supernus Pharmaceuticals, Inc. ("Parent"), and Saphire, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a cash tender offer to purchase all outstanding shares of common stock of the Issuer (each, a "Share") for (i) $8.50 per Share in cash (the "Closing Amount"), plus (ii) one contingent value right ("CVR") per Share, each without interest and subject to the withholding of applicable taxes, and thereafter merged with and into the Issuer, effective as of July 31, 2025 (the effective time of the merger, the "Effective Time"). (Continued from footnote 1) Each CVR represents the right to receive up to $3.50 per Share in cash upon the satisfaction of specified milestones, as described in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on June 16, 2025. Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares (a "Company Option") then outstanding and unexercised, whether or not vested, which had a per Share exercise price less than the Closing Amount was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment (without interest and subject to the withholding of applicable taxes) equal to the product of (a) the excess of the Closing Amount over the per Share exercise price of such Company Option, multiplied by (b) the total number of Shares subject to such Company Option immediately prior to the Effective Time, plus (ii) one CVR for each Share subject to such Company Option immediately prior to the Effective Time. Each Company Option, whether or not vested, which had a per Share exercise price greater than or equal to the Closing Amount was cancelled with no consideration payable in respect thereof.
